Axsome Therapeutics, Inc. (AXSM)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Dec 27, 2024

$86.70

P/E Ratio

N/A

Market Cap

$4.2B

Description

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerAXSM
  • Price$86.7-1.44%

Trading Information

  • Market cap$4.20B
  • Float81.74%
  • Average Daily Volume (1m)509,388
  • Average Daily Volume (3m)503,728
  • EPS-$6.54

Company

  • Revenue$338.46M
  • Rev growth (1yr)81.27%
  • Net income-$64.60M
  • Gross margin89.98%
  • EBITDA margin-42.16%
  • EBITDA-$44.17M
  • EV$4.19B
  • EV/Revenue12.38
  • P/EN/A
  • P/S12.33
  • P/B45.20
Documents